Needleless connector decontamination for prevention of central venous access device infection: A pilot randomized controlled trial - 19/01/21
, Julie Flynn a, b, c, d, Emily Larsen, GDHealthRes a, b, c, Gabor Mihala, GCBiostats a, e, E Geoffrey Playford, PhD a, f, Joanie Shaw, GCCancerNurs g, Samantha Keogh, PhD a, c, d, Amanda Ullman, PhD a, b, c, h, Li Zhang, PhD a, i, Nicole Gavin, PhD a, c, d, Tricia Kleidon, MN (NursePractitioner) a, b, h, Vineet Chopra, MD a, j, Alexandra L. McCarthy, PhD a, k, Patricia Kuerten Rocha, PhD a, l, Nicole Marsh, PhD a, b, cHighlights |
• | Central venous access devices need physical and chemical ‘scrub the hub’ before use. |
• | 70% isopropyl alcohol wipes had 2% Central Line Associated Bloodstream Infection. |
• | 70% isopropyl alcohol caps had 2% Central Line Associated Bloodstream Infection. |
• | Combined 70% isopropyl alcohol and 2% chlorhexidine gluconate wipe had no infection. |
• | Large randomised controlled trials of cleaning methods are feasible and needed. |
Résumé |
Pilot randomized controlled trial (180 patients) of needleless connector decontamination. Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients. Larger definitive trials are feasible and needed.
Le texte complet de cet article est disponible en PDF.Key Words : Catheterization, Central venous, Catheter related infections, Chlorhexidine gluconate, Isopropyl alcohol, Infection control
Plan
| Conflicts of Interest: C.M.R\220s employer, Griffith University, has received unrestricted investigator-initiated research grants on her behalf from (BD-Bard; Cardinal Health), and consultancy payments on her behalf from manufacturers (3M, BBraun, BD-Bard). E.L.\220s employer, Griffith University, has received on her behalf, an investigator-initiated grant from Cardinal Health (formerly Medtronic); E.L. has received an educational (conference) scholarship from Angiodynamics. S.K.\220s current employer (QUT) has received unrestricted educational grants on her behalf from product manufacturers (BD Medical). Griffith University (affiliated institution) has received consultancy payments on her behalf from manufacturers (BD Medical). A.J.U.\220s employer Griffith University has received unrestricted research grants and payments for educational lectures from 3M, Becton Dickinson [BD]-Bard, BBraun, and Cardinal Health on her behalf (unrelated to current project). T.M.K.\220s employer, Griffith University, has received funding on her behalf for investigator-initiated research or education grants from BD-Bard and Cardinal health; in addition to funding on her behalf for consultancy lectures or advice from 3M, Access Scientific, BD-Bard, Medical Specialties Australia and Vygon. V.C. has received grant support from the Agency for Healthcare Research and Quality and the American Hospital Association. He has also received royalties from Wolters Kluwer Health and Oxford University Press related to books he has authored. N.M.\220s previous employer Griffith University has received on her behalf investigator-initiated research grants from Becton Dickinson, and Cardinal Health and a consultancy payment provided to Griffith University from Becton Dickinson for clinical feedback all things (unrelated to the current project). No other conflicts to report. |
Vol 49 - N° 2
P. 269-273 - février 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
